EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudieOpen Access · CC BY 4.0

Pharmacokinetic comparison of ezetimibe/rosuvastatin/telmisartan 10/20/80 mg fixed-dose combination versus coadministration of separate tablets in healthy participants

Seoyoung Goh, Ki Young Huh, SeungHwan Lee, Joo-Youn Cho, Kyung-Sang Yu

Naunyn-Schmiedeberg's Archives of Pharmacology · 2026

DOI: 10.1007/s00210-025-04903-4 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2026. Verfasst von Seoyoung Goh und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Telmisartan, Ezetimibe, Rosuvastatin Calcium, Anticholesteremic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Seoul National University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study aimed to evaluate the pharmacokinetics (PKs) for fixed-dose combination (FDC) of ezetimibe/rosuvastatin/telmisartan 10/20/80 mg (test) compared to separate tablets of ezetimibe/rosuvastatin 10/20 mg FDC and telmisartan 80 mg (reference). A randomized, open-label, 4-period, 2-sequence replicated crossover study was conducted in healthy participants. Each treatment group received a single oral dose of test or reference drug in each period. PK samples during the 1st and 2nd periods were collected for all three drugs, while only telmisartan concentration was measured in the 3rd and 4th periods to evaluate intra-subject variability (ISV) of telmisartan. Geometric mean ratios (GMRs) of PK parameters and their 90% confidence intervals (CIs) were calculated with a linear mixed effect model between each treatment group. To account for the high ISV of telmisartan’s peak plasma concentration ( C max ), the scaled average bioequivalence (SABE) approach was considered in this analysis. A total of 58 participants were randomized, and 49 participants completed the study. PK profiles were comparable between treatments. The GMR and 90% CIs (test-to-reference) of area under the time-concentration curve and C max were 0.9835 (0.9260–1.0446) and 0.9873 (0.8830–1.1039) for free ezetimibe, and 0.9937 (0.9459–1.0440) and 1.0617 (0.9844–1.1415) for total ezetimibe. For rosuvastatin, corresponding values were 0.9465 (0.8883–1.0086) and 0.9062 (0.8135–1.0096); for telmisartan, 0.9728 (0.9315–1.0159) and 0.9724 (0.8846–1.0690), respectively. The result established equivalence without utilizing the SABE approach, although the ISV of telmisartan’s C max was 40.7%. A FDC of ezetimibe/rosuvastatin/telmisartan 10/20/80 mg demonstrated comparable pharmacokinetic profiles to corresponding separate treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TelmisartanEzetimibeRosuvastatin CalciumAnticholesteremic AgentsAngiotensin II Type 1 Receptor BlockersHumansMaleCross-Over StudiesAdultFemaleDrug CombinationsTabletsYoung AdultHealthy VolunteersArea Under CurveMiddle Aged

Stichwörter der Autor:innen

BioequivalenceDyslipidemiaFixed-dose combinationHypertensionPharmacokinetics

Substanzen

TelmisartanEzetimibeDrug CombinationsTabletsRosuvastatin CalciumAnticholesteremic AgentsAngiotensin II Type 1 Receptor Blockers

Autor:innen und Institutionen

  • Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea.
  • Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea. ksyu@snu.ac.kr.

Förderung

  • Seoul National University

Zitieren

APA

Goh, S., Huh, K. Y., Lee, S., Cho, J. Y., & Yu, K. S. (2026). Pharmacokinetic comparison of ezetimibe/rosuvastatin/telmisartan 10/20/80 mg fixed-dose combination versus coadministration of separate tablets in healthy participants. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-025-04903-4

Vancouver

Goh S, Huh KY, Lee S, Cho JY, Yu KS. Pharmacokinetic comparison of ezetimibe/rosuvastatin/telmisartan 10/20/80 mg fixed-dose combination versus coadministration of separate tablets in healthy participants. Naunyn-Schmiedeberg's Archives of Pharmacology. 2026. doi:10.1007/s00210-025-04903-4

BibTeX
@article{Goh2026,
  author = {Goh, Seoyoung and Huh, Ki Young and Lee, SeungHwan and Cho, Joo-Youn and Yu, Kyung-Sang},
  title = {Pharmacokinetic comparison of ezetimibe/rosuvastatin/telmisartan 10/20/80 mg fixed-dose combination versus coadministration of separate tablets in healthy participants},
  journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
  year = {2026},
  doi = {10.1007/s00210-025-04903-4}
}
Kostenlos starten →